Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Debt (2024 - 2025)

Apellis Pharmaceuticals has reported Total Debt over the past 2 years, most recently at $455.3 million for Q4 2025.

  • Quarterly results put Total Debt at $455.3 million for Q4 2025, up 26.66% from a year ago — trailing twelve months through Dec 2025 was $455.3 million (up 26.66% YoY), and the annual figure for FY2025 was $455.3 million, up 26.66%.
  • Total Debt for Q4 2025 was $455.3 million at Apellis Pharmaceuticals, roughly flat from $454.7 million in the prior quarter.
  • Over the last five years, Total Debt for APLS hit a ceiling of $455.3 million in Q4 2025 and a floor of $359.0 million in Q3 2024.